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https://doi.org/10.1016/j.stemcr.2018.08.015SUMMARYIn the case of organ transplantation accompanied by vascular anastomosis, major histocompatibility complex mismatched vascular
endothelial cells become a target for graft rejection. Production of a rejection-free, transplantable organ, therefore, requires simultaneous
generation of vascular endothelial cells within the organ. To generate pluripotent stem cell (PSC)-derived vascular endothelial cells, we
performed blastocyst complementation with a vascular endothelial growth factor receptor-2 homozygous mutant blastocyst. This mutation
is embryonic lethal at embryonic (E) day 8.5–9.5 due to an early defect in endothelial and hematopoietic cells. The Flk-1 homozygous
knockout chimeric mice survived to adulthood for over 1 year without any abnormality, and all vascular endothelial cells and hemato-
poietic cells were derived from the injected PSCs. This approach could be used in conjunction with other gene knockouts which induce
organ deficiency to produce a rejection-free, transplantable organ in which all the organ’s cells and vasculature are PSC derived.INTRODUCTION
Two key constraints to successful treatment using human
organ transplantation are graft rejection and organ
shortage. Autologous tissue stem cells or cell sheets gener-
ated from patient-derived induced pluripotent stem cells
(iPSCs) have been transplanted to eliminate rejection-asso-
ciated problems. Unfortunately, these cell therapies are
often not adequate to repair or replace a failing organ
(Assawachananont et al., 2014; Takebe et al., 2013).
Blastocyst complementation can be used to generate
entire organs derived from pluripotent stem cells (PSCs).
In this method, PSCs are injected into a blastocyst that
has been genetically modified to prevent development of
a targeted organ (Kobayashi et al., 2010; Matsunari et al.,
2013; Usui et al., 2012; Yamaguchi et al., 2017). The PSCs
integrate into the growing embryo to form a chimeric ani-
mal; however, the targeted organ develops exclusively from
the injected PSCs.
We first successfully generated PSC-derived organs using
blastocyst complementation in 2010. To target the
pancreas we knocked out Pdx1, resulting in apancreatic
mice with severe hyperglycemia that died within a week
after birth. We rescued this phenotype by injecting mouse
or rat PSCs into the Pdx1 knockout (KO)mouse blastocysts.988 Stem Cell Reports j Vol. 11 j 988–997 j October 9, 2018 j ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://creativNearly all pancreatic cells, including exocrine and endo-
crine cells, were derived from the injected PSCs. However,
cells originating from non-pancreatic lineages, such as
blood vessels and stromal cells, were chimeric for both blas-
tocyst-derived cells and PSC-derived cells (Kobayashi et al.,
2010). We had similar results when targeting the kidney
with blastocyst complementation—the renal lineage cells
were derived from injected PSCs, whereas non-renal line-
ages within the kidneys were chimeric (Usui et al., 2012).
Amajor histocompatibility complex (MHC)mismatch of
the vascular endothelial cells (a monolayer of cells lining
the lumen of vessels) will elicit hyperacute rejection
against the blood vessel endothelium in the transplanted
organ. Hyperacute rejection often occurs within 24 hr
and is initiated by recipient’s natural antibodies against
the antigens present in the graft’s vascular endothelial cells.
After recognition of the antigens, the complement and
coagulation systems are activated, resulting in inflamma-
tion and vascular occlusion. This will cause the graft to
rapidly necrose. Between 6 days and 3 months after trans-
plantation, acute rejection may occur, which is also caused
by an MHC mismatch of the vascular endothelial cells.
Acute rejection caused by effector T cells, antibodies, and
activated Tcells will directly lyse the graft’s vessels and pro-
duce cytokines that recruit and activate inflammatory cellsuthors.
ecommons.org/licenses/by-nc-nd/4.0/).
(Platt et al., 1990, 1991). Therefore, in the context of blas-
tocyst complementation, it is necessary to generate organs
together with vascular endothelial cells in the blood vessels
from a patient’s iPSCs to prevent organ rejection.
In this study, we aimed to generate blood vessels contain-
ing entirely PSC-derived vascular endothelial cells by blas-
tocyst complementation. In mice, vasculogenesis is
initiated from the yolk sac blood islands at E7.5 and is
dependent on several key factors. Disrupting vascular endo-
thelial growth factor receptor 2 (VEGFR2/Flk-1/KDR) inhibits
vasculogenesis due to impaired endothelial and hemato-
poietic cell development, resulting in embryonic lethality
around E9.0 (Shalaby et al., 1995, 1997). Since Flk-1mutant
mice (Flk-11173F/1173F) represent the same phenotype as a
Flk-1 KO mice, Flk-1 mutant blastocysts were used as our
host embryo for blastocyst complementation (Sakurai
et al., 2005).RESULTS
Flk-11173F/1173F miPSC-Derived Cells Cannot
Contribute to PECAM1-Expressing Vascular
Endothelial Cells in Adult Mice
Although the Flk-1 homozygous mutant (or Flk-11173F/1173F)
mouse is well studied at early embryonic stages, because of
embryonic lethality at E8.5–9.5, the role of Flk-1 in vasculo-
genesis from E9.5 to adulthood is unclear. To address this
issue, we generated chimeric mice by injecting enhanced
green fluorescent protein (EGFP)-marked Flk-11173F/1173F
mouse-induced PSCs (miPSCs) into wild-type (WT) mouse
blastocysts (Figures S1A and S1B). We first analyzed the
contribution of Flk-11173F/1173F cells to blood vessels in
E13.5 embryos (Figures 1A and 1B). The immunofluores-
cent staining of a section of intestine with relatively
high chimerism revealed that the EGFP-expressing
Flk-11173F/1173F iPSC-derived cells did not express platelet
endothelial cell adhesion molecule 1 (PECAM1) (arrow)
(Figure 1A). In addition, flow cytometric analysis of fetal
liver showed that the CD45 and PECAM1+ (also known
as CD31) vascular endothelial cells did not express
EGFP (Figure 1B).Next, in order to analyze the contribution
of Flk-11173F/1173F iPSCs in adult chimeric mice, we per-
formed immunofluorescent analysis of a pancreas that
showed relatively high chimerism and found that EGFP+
Flk-11173F/1173F iPSC-derived cells did not express PECAM1
(Figures 1C, S1C, and S1D).
These results indicate that Flk-11173F/1173F iPSC-derived
cells cannot contribute to vasculogenesis or angiogenesis
from the early embryo to adulthood. Thus, the Flk-
11173F/1173F mouse is a suitable host animal for blastocyst
complementation when generating PSC-derived blood
vessels.mPSCs Can Rescue Flk-1 KO Lethality by Blastocyst
Complementation
To generate blood vessels in Flk-11173F/1173F mice, blasto-
cysts and morulae obtained from an intercross of Flk-
1+/1173F mice were injected with EGFP or KuO-labeled
miPSCs or mouse embryonic stem cells (mESCs). A total
of 105 chimeric mice were born and matured to adults
with no remarkable abnormalities. Of these, 11 were Flk-
11173F/1173F, indicating that mPSCs can contribute to vascu-
logenesis and rescue the Flk-1 KO phenotype (Table 1).
Immunofluorescence was used to analyze the distribu-
tion of miPSC-derived cells in each tissue. In the Flk-
11173F/1173F chimeric mice, PECAM1+ vascular endothelial
cells in the aorta, kidney, lung, and heart were entirely
derived from miPSCs. Other structures not of the vascular
endothelial lineage, such as vascular smooth muscle in
the aorta, Bowman’s capsule and renal tubule in the kidney,
bronchioles and alveoli in the lung, and myocardium in
the heart, were a composite of host and donor derivatives
(Figures 2A, 2C, 2E, 2F, S2A, S2B, and S2E). In expected
contrast, all structural components, including vascular
endothelial cells of the aorta, kidney, lung, and heart in
Flk-1+/1173F chimeric mice, were a composite of host and
donor derivatives (Figures 2B, 2D, 2G, 2H, S2C, S2D,
and S2F).
To further analyze the contribution of mPSCs to vascular
endothelial cells, we performed fluorescence-activated cell
sorting (FACS) analysis of enzymatically dissociated tissues
from adult chimeric mice.
In Flk-11173F/1173F chimeric mice, almost 100% of the
vascular endothelial cell population (CD45/PECAM1+)
of the lungs, kidneys, and aortas were EGFP positive (Fig-
ures 3A, S3A, and S3B), whereas populations other than
vascular endothelial cells (CD45/PECAM1 population),
the cells in the vessel wall, or the perivascular cells
(CD45/PECAM1/platelet-derived growth factor receptor
beta [PDGFR b+]) and the overall cells in the lungs, kidneys,
and aortas were chimeric (39.8%–95.7%) (Figures 3B, 3C,
S3A, and S3B).
These results indicate that themPSCs could complement
the vasculogenic niche and create functional blood vessels
in Flk-11173F/1173F mice. Moreover, the vascular endothelial
cells in blood vessels were completely derived frommPSCs,
whereas the other components were composed of host and
donor-derived cells. This means whole chimera mouse
body was not composed of almost 100% donor cells and
successfully complemented specific tissue by blastocyst
complementation. Although we tried to generate rat
vascular endothelial cells in mice by injecting rat PSCs
into Flk-11173F/1173Fmouse blastocysts, we could not obtain
live Flk-11173F/1173F fetuses at E13.5 and beyond. However,
at E9.5, live Flk-11173F/1173F interspecies chimeric fetuses
were found at Mendelian ratios (Table S1).Stem Cell Reports j Vol. 11 j 988–997 j October 9, 2018 989
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Figure 1. Phenotype of Vasculogenesis in Flk-11173F/1173F iPSC-Derived Chimeric Mice
(A) Immunohistological analysis of vascular endothelial cells in embryo of Flk-11173F/1173F iPSC-derived chimeric mouse at E13.5. Sections
were stained with antibodies against GFP for Flk-11173F/1173F iPSC-derived cells, and PECAM1 for endothelial cells, and cell nuclei were
stained with DAPI. The vascular endothelia are indicated (arrows).
(B) Flow cytometry analysis of vascular endothelial cells in fetal liver. Fetal liver cells were stained with antibodies against CD45 and
PECAM1. Representative results from n = 8 independent experiments are shown.
(C) Immunohistological analysis of sections obtained from pancreas. Sections were stained with antibodies against GFP for Flk-11173F/1173F
iPSC-derived cells, antibodies against PECAM1 for endothelial cells (arrows) and DAPI for nuclear counterstaining. Lower panels show
higher magnification.
Scale bars: 50 mm (A) and 100 mm (C).
990 Stem Cell Reports j Vol. 11 j 988–997 j October 9, 2018
Table 1. Generation of Flk-11173F/1173F Chimera Mice by
Blastocyst Complementation
Injected
Cell Lines
No. (%) of
Offsprings Flk-1 Genotype (%)
Alive Chimeras +/+ +/1173F
1173F/
1173F NDa
GT3.2 48 37 (77) 13 (35) 20 (54) 4 (11) 0 (0)
KuOmiPS 20 13 (65) 9 (69) 3 (23) 1b (8) 0 (0)
SGE2 56 55 (98) 14 (25) 18 (33) 6 (11) 17 (31)
Total 124 105 (85) 36 (34) 41 (39) 11 (11) 17 (16)
aNot determined.
bNeonate.All Hematopoietic Stem Cells in the Flk-11173F/1173F
Chimeric Mouse Were Generated from Donor mPSCs
It was previously reported that the Flk-11173F/1173F mouse
has an embryonic lethal phenotype due to not only
impaired vasculogenesis, but also deficient primitive
hematopoiesis at E8.5 to E9.5. Therefore, we analyzed
the contribution of mPSCs in CD45+ hematopoietic
cells to confirm whether the hematopoietic cells are
also completely derived from injected mPSCs in Flk-
11173F/1173F chimeric mice. FACS analysis of peripheral
blood mononuclear cells (PBMCs) revealed that all line-
ages of hematopoietic cells were almost 100% EGFP
positive in Flk-11173F/1173F chimeric mice, whereas he-
matopoietic cells in Flk-1+/1173F chimeric mice were
chimeric. Similar results were obtained by the FACS anal-
ysis of splenocytes (Figures 4A, S4A, and S4B). We also
analyzed the percentage of EGFP+ cells in, c-Kit+, Sca-1+,
and lineage (KSL) hematopoietic progenitor and stem
cells. We found that the chimerism of EGFP+ cells in the
KSL population was 100% in Flk-11173F/1173F chimeric
mice and chimeric in Flk-1+/1173F chimeric mice (Figures
4B, S4C, and S4D). Furthermore, to analyze the reconsti-
tution ability of miPSC-derived hematopoietic stem cells
(HSCs) generated in Flk-11173F/1173F chimeric mice, we per-
formed transplantation of the Flk-11173F/1173F chimera’s
whole bone marrow to sub-lethally irradiated recipient
mice (n = 4) and analyzed the engraftment rate. The trans-
planted cells differentiated into three hematopoietic line-
ages, including B cell, T cell, and myeloid cells. The
percentage of EGFP+ cells in hematopoietic cells was
98%; in B cells was 100%; in T cells was 92.3%; and in
myeloid cells was 98.9% (Figures 4C and 4D).
These results indicate that mPSCs can complement
both the hematopoietic and vasculogenic niche, gener-
ating entirely mPSC-derived HSCs and hematopoietic
cells in Flk-11173F/1173F chimeric mice by blastocyst
complementation.DISCUSSION
Here we successfully used blastocyst complementation to
generate mPSC-derived vascular endothelial cells and he-
matopoietic cells, including HSCs.
In order to generate Flk-11173F/1173F chimeric mice, fluo-
rescently labeled WT mPSCs were injected into blasto-
cysts/morulae obtained by intercross of a Flk-1+/1173F male
with a Flk-1+/1173F female mouse. The birth rate of Flk-
11173F/1173F chimeric mice was distorted from Mendelian
expectations. This distortion was also observed in E13.5
to E15.5 chimeric fetuses (4/90 = 4.4%). We previously
found that the birth rate of Pdx1/ chimeric mice obey
Mendel’s law (Kobayashi et al., 2010), suggesting that
complementation efficiency may depend on the targeted
gene. For example, although the size of the pancreas may
be restricted by the number of cells present in the pancre-
atic anlage, we previously observed that a small pancreas
is enough to maintain blood glucose level (data not
shown), indicating that the contribution rate of PSCs to
pancreatic anlagemight not affect the birth rate of comple-
mentedmice. On the other hand, Flk-1 is important for the
development of multiple tissues that are dispersed
throughout thewhole body, including vascular endothelial
cells, hematopoietic cells, and smoothmuscle cells. Hence,
the contribution rate of PSCs to the vascular endothelial
cell anlage might affect the survival of the developing
mouse.
Although we successfully generated entirely PSC-derived
vascularendothelial cells, thevesselwall and theperivascular
cells,which includesmoothmusclecells, pericytes, andrenal
mesangial cells, were chimeric because those tissues can
develop from both host neural crest and Flk-1+ mesoderm
cells (Hirschi and Majesky, 2004; Nakamura et al., 2006).
When performing blastocyst complementation with Flk-
11173F/1173F mouse embryos, all hematopoietic cells were
entirely derived from the injected mPSCs. Primitive hema-
topoiesis is initiated in the yolk sac blood island at E7.5.
The site of hematopoiesis is then migrated to the aorta-
gonad-mesonephros (AGM) region, after which definitive
hematopoiesis is initiated around E10.5. Previous studies
showed that HSCs first emerge from vascular endothelial
cells in the dorsal aorta at E10.5 (Bertrand et al., 2010; Bois-
set et al., 2010; Herbert et al., 2009; Kissa and Herbomel,
2010). When performing blastocyst complementation
with Flk-11173F/1173F mouse embryos, the HSCs likely
emerged from the complemented vascular endothelial
niche, resulting in generation of both PSC-derived vascular
endothelial cells and hematopoietic cells. Because residual
hematopoietic cells left in a graft might induce graft versus
host disease (GVHD) after transplantation, simultaneous
generation of tissue and hematopoietic cells from PSCs
might further reduce the risk of GVHD.Stem Cell Reports j Vol. 11 j 988–997 j October 9, 2018 991
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Figure 3. Flow Cytometry Analysis of the EGFP-Expressing, miPSC-Derived Cells in the Vascular Endothelium and Pericytes of Each
Organ
Ratio of donor cell contribution in lung, kidney and aorta of Flk-11173F/1173F or Flk-1+/1173F chimeric mice were analyzed using antibodies
against CD45, PECAM1, and PDGFRb.
(A) Vascular endothelial cells (CD45/PECAM1+) were gated and analyzed for EGFP expression.
(B) Non-vascular endothelial cells (CD45/PECAM1) were gated and analyzed for EGFP expression.
(C) Pericytes (CD45/PECAM1/PDGFRb+) were gated and analyzed for EGFP expression.
Red line, Flk-11173F/1173F chimeric mouse; blue line, Flk-1+/1173F chimeric mouse; gray dashed-line, C57BL/6 mouse shown as a control.
Three biological replicates were performed.Although most of the PBMCs from Flk-11173F/1173F
chimeric mice were EGFP positive, FACS analysis revealed
that 0.2% to 1.3% of hematopoietic cells were EGFP nega-
tive. We found that the HSCs in the bone marrow ofFigure 2. Immunohistological Study of Chimeric Mice at Adult St
(A–D) The distribution of iPSC-derived cells in sections of aorta a
GFP, PECAM1, a-SMA, and DAPI. L, lumen; BV, blood vessel; G, glom
(A, B, E, and G).vascular system complemented Flk-11173F/1173F chimera
mouse were 100% EGFP positive. Moreover, EGFP-negative
hematopoietic cells were also observed in peripheral blood
of the EGFP transgenic mouse, which is the origin of donorage
nd kidney (E–H). Sections were stained with antibodies against
erulus; T, tubules. Scale bars: 50 mm (C, D, F, and H) and 100 mm
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PSCs. These results indicate that gene silencing had
occurred in EGFP-negative hematopoietic cells in periph-
eral blood of rescued Flk-11173F/1173F chimera mice. In
addition, there is another possibility that EGFP-negative
hematopoietic cells were derived from the origin other
than HSCs, as previously described (Ginhoux et al., 2010;
Hoeffel et al., 2012).
Because our goal is to generate tissues or organs in a xeno-
genic animal, we also tried tomake rat vascular endothelial
cells and hematopoietic cells in mice by injecting rat iPSCs
into mouse blastocysts obtained by an intercross of Flk-
1+/1173Fmice. Because Flk-11173F/1173Fmicewere embryonic
lethal at E8.5E9.5, even the incomplete complemented
embryos were viable until E9.5 and follow Mendelian
laws. Because incomplete complementation leads to imma-
ture vascularization and embryonic death after E9.5, the
birth rate of Flk-11173F/1173F chimeric mice and survival
rate of E13.5–E15.5 chimeric fetuses were distorted from
Mendelian expectations in both intraspecies complemen-
tation and interspecies complementation setting. The
incomplete contribution of donor cells to the AGM region
can induce embryonic death because the ischemic condi-
tion is causedbyhematopoietic cell andvascular deficiency.
Although mPSCs can rescue the Flk-11173F/1173F pheno-
type in mouse blastocysts, efficiency is low. Efficiency
could be immediately increased by abandoning the hetero-
zygous intercross approach, which results in only 25% Flk-
11173F/1173F blastocysts. Instead, adopting nuclear transfer
technology or utilizing Flk-1-driven suicide genes would
result in 100% Flk-1-deficient embryos. These approaches
are also useful for performing multiple gene disruptions.
Currently, organs transplanted into human patients are
supplied by human donors. These allogeneic grafts may
be rejected and require each recipient to endure lifelong
immunosuppression. By simultaneously disrupting Flk-1
and genes required for organogenesis (e.g, Pdx1 for
pancreas), autologous organs could be generated from
patient-specific iPSCs via interspecies blastocyst comple-
mentation. These iPSC-derived organs would not be
contaminated with xenogenic cells in the vascular endo-
thelium, eliminating rejection-associated problems (PlattFigure 4. Flow Cytometry Analysis of Chimerism in miPSC-Derive
(A) Representative flow cytometric plots of EGFP and hematopoietic l
Flk-1 mutant chimeras. Three biological replicates were performed.
(B) Representative flow cytometric plots and gating for the c-Kit+Sca
Three biological replicates were performed.
(C) Representative percentage of peripheral blood chimerism of 12 w
irradiated four recipient mice.
(D) Time course of engraftment of complemented hematopoietic cells
8, and 12 weeks after transplantation.
Results are means ± SD of n = 4 (Flk-11173F/1173F; 4 weeks), n = 3 (F
(Flk-1+/1173F; 4 weeks), n = 3 (Flk-1+/1173F; 8 weeks), and n = 3 (Flk-1et al., 1990, 1991). Chimeric animal models generated
from Flk-1 deficient blastocysts thus provide a key step
toward in vivo generation of rejection-free organs for use
in regenerative medicine.EXPERIMENTAL PROCEDURES
Animals
C57BL/6NCrSlc, BDF1, ICR mice were purchased from SLC Japan
(Shizuoka, Japan). Flk-1+/1173F mice were kindly provided by
Dr. M. Shibuya (University of Tokyo, Tokyo Medical and Dental
University, and Jobu University) (Sakurai et al., 2005), and were
crossed with C57BL/6 or BDF1 mice. All experiments were per-
formed in accordance with the animal care and use committee
guidelines of the Institute of Medical Science, University of Tokyo.Culture of iPSCs/ESCs
Undifferentiatedmouse iPSCs (GT3.2(XY) (Kobayashi et al., 2010),
mESCs (SGE2) derived from EGFP transgenic mice, Flk-11173F/1173F
miPSCs, and Kusabira Orange (KuO) miPS) were maintained on
mitomycin C-treated mouse embryonic fibroblast (MEF) feeder
cells in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis,
MO) supplemented with 15% fetal bovine serum (Nichirei Biosci-
ence, Tokyo, Japan), 0.1 mM 2-mercaptoethanol (Invitrogen, San
Diego, CA, USA), 1% nonessential amino acids (Invitrogen),
1 mM sodium pyruvate (Invitrogen), 1% L-glutamine penicillin
streptomycin (Sigma), and 1,000 U/mL of mouse leukemia inhibi-
tory factor (LIF; Millipore, Bedford, MA, USA).
Flk-11173F/1173F miPSCs were generated from embryonic fibro-
blasts harvested from an E13.5 Flk-11173F/1173F chimeric mouse
fetus (injected with GT3.2 iPSCs at the blastocyst stage). The iPSCs
were generated by introducing three reprograming factors (Oct-
3/4, Sox-2, and Klf-4) and EGFP in all-in-one inducible lentiviral
vector (Ai-LV) (Yamaguchi et al., 2012).
KuO miPS were generated from MEFs of KuO mice by intro-
ducing three reprograming factors (Oct-3/4, Sox-2, and Klf-4) in
Ai-LV and CAG huKO IRES Puro (Hamanaka et al., 2013).
riPST1-3 were generated from rat embryonic fibroblasts ofWistar
rat by introducing three reprograming factors (Oct-3/4, Sox-2, and
Klf-4) in Ai-LV (Hamanaka et al., 2011). Fri6.1 were generated from
rat embryonic fibroblasts of F344 rat by introducing three reprog-
raming factors (Oct-3/4, Sox-2, and Klf-4) in pMx mOKS IRES
tdTomato and CAG huKO IRES Puro.d Hematopoietic Cells
ineage marker expression in peripheral blood and splenocytes from
1+Lineage (KSL) fraction within the BM of Flk-1 mutant chimeras.
eeks after Flk-1 mutant chimera’s BM transplantation into lethally
are shown. EGFP expression was analyzed in the peripheral blood 4,
lk-11173F/1173F; 8 weeks), n = 2 (Flk-11173F/1173F; 12 weeks), n = 3
+/1173F; 12 weeks) independent experiments.
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Maintenance of rat iPSCs has been previously described (Hama-
naka et al., 2011). Briefly rat iPSCs were maintained onmitomycin
C-treated MEF feeder cells in N2B27 medium (Invitrogen) supple-
mentedwith 1,000U/mLmouse LIF (Millipore, Bedford,MA, USA)
or rat LIF (Rat ESGRO; Millipore ESG 2206), 1 mM GSK3 inhibitor
CHIR99021 (Axon Medchem),1 mM MEK inhibitor PD0325901
(Stemgent or Wako), 1% L-glutamine penicillin streptomycin
(Sigma). All PSC lines were authenticated by chimera formation.
Generation of Chimeric Mice and Genotyping of
iPSCs/ESCs Derived from Chimeric Mice
Chimericmicewere generated by injection ofmiPSCs into 3.5 days
post coitum (dpc) blastocysts and mESCs into 2.5 dpc morulae of
WT or Flk-1+/1173F intercrossing embryos, followed by transfer
into host uteri as previously described (Kobayashi et al., 2010)
For genotyping, chimeric mouse fibroblasts were isolated from
E13.5–E14.5 mice and adult mice. GFP mouse fibroblasts were
sorted by cytometry using MoFlo or Aria cytometer (Beckman
Coulter, Fullerton, CA, USA). Genotypes of mice were confirmed
using extracted genomic DNA from sorted GFP-expressing cells.
PCR primers for amplification of Flk-1 were forward; 50-GCCT
CTTCCAAGACAGTCT-30 and reverse; 50-GAACCTTCAGCAGGT
TTCCTATTTG-30. After BspEI digestion of the PCR products
(729 bp), the products from the WT allele were not digested
(729 bp), but the products from the Flk-11173F mutant allele were
digested into 523 and 206 bp bands.
Histological Analysis
For frozen sections, mouse tissues were fixed with 4% paraformal-
dehyde, washed with PBS, soaked in 30% sucrose and mounted in
optimal cutting temperature compound (Sakura Finetek, Tokyo,
Japan). Frozen sections were stained immunohistochemically.
Each section was incubated with the primary antibody overnight
at 4C and with the secondary antibody for 1 hr at room
temperature.
The antibodies used for the primary antibody were antibodies
against EGFP (A11122, Invitrogen; and ab6673, Abcam,Cambridge,
UK), platelet endothelial cell adhesion molecule-1 (PECAM1,
#550274, BD PharMingen, Franklin Lakes, NJ, USA), and a-smooth
muscle actin (aSMA, ab5694, Abcam). Secondary antibodies used
were Alexa 488-conjugated-goat anti-rabbit IgG (A11034), -donkey
anti-rabbit IgG (A21206), -donkey anti-goat IgG (A11055), Alexa
546-conjugated-goat anti-rat IgG (A11081), -donkey anti-rabbit
IgG (A10040), Alexa 647-conjugated-goat anti-rabbit IgG
(A21245), -chicken anti-rat IgG (A21472) (Invitrogen). After anti-
body treatment, sections were counterstained with 40,6-diami-
dino-2-phenylindole (DAPI, Sigma) andmountedwithfluorescence
mounting medium (Dako, Glostrup, Denmark). The sections
were observed under fluorescence microscopy (BZ9000, Keyence,
Itasca, IL)
Flow Cytometry Analysis of iPSC/ESC-Derived
Chimeras and Bone Marrow Transplantation
Cells were dissociated with accutase (Innovative Cell Technolo-
gies, San Diego, CA) for fetal liver, with accutase or trypsin for em-
bryonic fibroblast, and with collagenase IA for adult tissues. Cells
were stained with phycoerythrin (PE)-conjugated anti-CD3 3996 Stem Cell Reports j Vol. 11 j 988–997 j October 9, 2018(#100307), -CD45.2 (#109807) (BioLegend, San Diego, CA) and
-CD31 (PECAM1, #12-0311-81, eBioscience, San Diego, CA), allo-
phycocyanin (APC)-conjugated anti-CD45 (#559864, BD Phar-
mingen, Franklin Lakes, NJ), -CD45.1 (#17-0453-82, eBioscience)
and -CD140b (PDGFRb, #136008, BioLegend), phycoerythrin
cyanine7 (PECy7)-conjugated anti-CD45 (#103113, BioLegend,
or #25–0451081, eBioscience), -Gr-1 (#108415) and -Mac-1
(CD11b, #101215), Pacific blue (PB)-conjugated anti-CD45
(#103126) and B220 (#163230) (BioLegend), brilliant violet (BV)-
421-conjugated anti-CD31 (#563356, BD Bioscience, San Jose,
CA), allophycocyanin cyanine7 (APC-Cy7)-conjugated anti-CD3
(#100221, BioLegend), and purified-CD16/32 (#553142, BD Phar-
mingen) antibodies, and propidium iodide for removing dead
cells. HSCs were stained with APC-conjugated anti-c-Kit (#17-
1171-81, eBioscience), PE-conjugated anti-Sca-1 (#108108), PB-
conjugated anti-Sca-1 (#108119) (BioLegend), and the lineage
antibody-mix consisting of biotinylated anti-Gr-1 (#13593185),
-Mac-1 (#13011285), -CD4 (#13004285), -Ter119 (#13592185),
-interleukin-7 receptor (#13127185) (eBioscience), and -CD8
(#13008185) and -B220 (#13045285) (BioLegend) antibodies.
The biotinylated antibodies were developed with streptavidin-
APC-Cy7 (#405208, BioLegend).
After being washed with PBS containing 2% fetal calf serum
(FCS), stained cells were analyzed by flow cytometry using Cant
II or Aria II equipment (Becton-Dickinson, Franklin Lakes, NJ).
For bone marrow (BM) transplantation, total BM cells were sus-
pended in 2% FCS in PBS; 2 3 107 total BM cells in 200 mL of me-
dium was injected into each of a group of lethally irradiated
C57BL/6 mice. Peripheral blood cells of the recipient mice were
analyzed 4, 8, and 12 weeks after transplantation.
Statistics and Reproducibility
The experiments were not randomized and the investigators were
not blinded to allocation during experiments and outcome assess-
ment. Statistical significance was calculated by F test and Student’s
t test (compare two groups) and the similarity to theMendelian ra-
tio was analyzed by chi-squared test (with Excel and GraphPad
Prism software). p < 0.05 was considered to be statistically signifi-
cant. Data are presented as mean ± SD.
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